Expert Pitch
University of Michigan

Jason Pogue: Operation Warp Speed targets a COVID-19 vaccine by January; much still unknown

11-May-2020 10:35 AM EDT, by University of Michigan

FACULTY Q&A

ANN ARBOR–In late April, the federal government announced Operation Warp Speed, an aggressive COVID-19 vaccine development program that aims to have at least 300 million doses of vaccine available in the United States by January. Jason Pogue, clinical professor of pharmacy, discusses the feasibility of this aggressive timetable.

Is this timeframe possible?

It is impossible to say if it is possible, because there are too many unknowns. This is a first: No vaccine development has approached this rapid of a timeline––however, never have we seen a program afforded this many resources. While I am skeptical of the timeline, I remain hopeful and somewhat optimistic that we can have some amount of vaccine at some point in 2021 in the United States. Then, decisions on prioritizing who is vaccinated (high-risk populations, essential workers, disease epicenters) and potential global collaboration/cooperation with vaccines in development abroad will be critical.

What are some of the unknowns?

First and foremost, we do not know if the handful of leads that the U.S. will focus on will be safe and effective. Clinical trials are essential to determine the safety and efficacy, and even though the plan is to perform them in a faster timeline, everything depends on whether the vaccine works.

I also think there will be some unique challenges in determining the efficacy of a vaccine during a pandemic, particularly with so many unknowns about the causative pathogen. For example, to show that a vaccine works you must demonstrate that significantly fewer patients taking the vaccine become infected with SARS CoV-2, compared to controls. However, if these studies don’t occur until summer or fall, unknowns about the seasonality of the virus could impact the number of patients who get infected.

Furthermore, the control arm infection rate will largely be determined by the trajectory of COVID-19 months from now, and we do not know that. Additionally, we’ve learned that patients can be asymptomatically infected, and studies must capture this. Also, you’d need to control for social distancing, the density of infections in the patients’ region, mask use, and other factors that may change during the study, and influence the infection rate. These add complexities to the rapid timeline.

Additionally, it’s unknown how quickly the ramp-up phase would proceed, and it’s possible that the most successful manufacturers have the least effective vaccine. So, we could have different amounts of different vaccines with different degrees of protection. A coordinated distribution will be critical.

Won’t the U.S. face the same supply chain problems that have plagued the implementation of widespread testing?

I am not clear what supplies are needed for vaccine development and the relative abundance of each of them. However, with global efforts being made at vaccine development, it’s reasonable to believe that supply chain problems could arise.

How effective does a vaccine need to be to promote herd immunity and stop spread?

The better question is, “What percent of the population must have immunity for an infection to die out?” This is called herd immunity, and many variables contribute to it. Some of those variables include the percent of the population that’s immune (either via vaccine or through natural infection), and how infectious the pathogen is (which can be modified based on social distancing and other preventative measures.)

In my opinion, we’ll be dealing with COVID-19 to some degree for the foreseeable future. There are many unknowns, including the degree/duration of protection antibodies and cellular immunity provide.

With that said, even a suboptimal vaccine can benefit the population. The annual efficacy of the seasonal flu vaccine is usually 40% to 50%, and many experts consider it a poor vaccine. However, it prevents millions of influenza cases annually and can also decrease the illness’ severity in those who become infected.

https://pharmacy.umich.edu/people/jmpogue

Studio available




Filters close

Showing results

110 of 2525
Newswise: Pandemic Inspires Framework for Enhanced Care in Nursing Homes
Released: 10-Jul-2020 12:25 PM EDT
Pandemic Inspires Framework for Enhanced Care in Nursing Homes
University of Pennsylvania School of Nursing

As of May 2020, nursing home residents account for a staggering one-third of the more than 80,000 deaths due to COVID-19 in the U.S. This pandemic has resulted in unprecedented threats—like reduced access to resources needed to contain and eliminate the spread of the virus—to achieving and sustaining care quality even in the best nursing homes. Active engagement of nursing home leaders in developing solutions responsive to the unprecedented threats to quality standards of care delivery is required.

Newswise: General Electric Healthcare Chooses UH to Clinically 
Evaluate First-of-its-kind Imaging System
Released: 10-Jul-2020 12:15 PM EDT
General Electric Healthcare Chooses UH to Clinically Evaluate First-of-its-kind Imaging System
University Hospitals Cleveland Medical Center

University Hospitals Cleveland Medical Center physicians completed evaluation for the GE Healthcare Critical Care Suite, and the technology is now in daily clinical practice – flagging between seven to 15 collapsed lungs per day within the hospital. No one on the team could have predicted the onset of the COVID-19 pandemic, but this technology and future research with GEHC may enhance the capability to improve care for COVID-19 patients in the ICU. Critical Care Suite is now assisting in COVID and non-COVID patient care as the AMX 240 travels to intensive care units within the hospital.

Released: 10-Jul-2020 11:50 AM EDT
COVID-19 Can Be Transmitted in the Womb, Reports Pediatric Infectious Disease Journal
Wolters Kluwer Health: Lippincott Williams and Wilkins

A baby girl in Texas – born prematurely to a mother with COVID-19 – is the strongest evidence to date that intrauterine (in the womb) transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can occur, reports The Pediatric Infectious Disease Journal, the official journal of The European Society for Paediatric Infectious Diseases. The journal is published in the Lippincott portfolio by Wolters Kluwer.

Released: 10-Jul-2020 9:45 AM EDT
How COVID-19 Shifted Inpatient Imaging Utilization
Harvey L. Neiman Health Policy Institute

As medical resources shifted away from elective and non-urgent procedures toward emergent and critical care of COVID-19 patients, departments were forced to reconfigure their personnel and resources. In particular, many Radiology practices rescheduled non-urgent and routine imaging according to recommendations from the American College of Radiology (ACR). This new Harvey L. Neiman Health Policy Institute study, published online in the Journal of American College of Radiology (JACR), evaluates the change in the inpatient imaging volumes and composition mix during the COVID-19 pandemic within a large healthcare system.

access_time Embargo lifts in 2 days
Embargo will expire: 12-Jul-2020 7:00 PM EDT Released to reporters: 10-Jul-2020 9:00 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 12-Jul-2020 7:00 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 10-Jul-2020 9:00 AM EDT
Team is first in Texas to investigate convalescent plasma for prevention of COVID-19 onset and progression
University of Texas Health Science Center at Houston

A research team is the first in Texas to investigate whether plasma from COVID-19 survivors can be used in outpatient settings to prevent the onset and progression of the virus in two new clinical trials at UTHealth.

Newswise: Commentary in Pediatrics: Children Don’t Transmit Covid-19, Schools Should Reopen in Fall
7-Jul-2020 3:00 PM EDT
Commentary in Pediatrics: Children Don’t Transmit Covid-19, Schools Should Reopen in Fall
University of Vermont

Based on one new and three recent studies, the authors of this commentary in Pediatrics conclude that children rarely transmit Covid-19, either among themselves or to adults. The authors recommend that schools reopen in the fall, since staying home can adversely affects children's development.

Newswise: Team Sports Risks Go Well Beyond Injury During the Pandemic
Released: 9-Jul-2020 6:25 PM EDT
Team Sports Risks Go Well Beyond Injury During the Pandemic
University of California, Los Angeles (UCLA), Health Sciences

Annabelle de St. Maurice, MD, MPH, co-chief infection prevention officer for UCLA Health, speaks on The Centers for Disease Control and Prevention's guide for youth sports to resume.


Showing results

110 of 2525

close
1.00692